{
    "nct_id": "NCT05116202",
    "official_title": "A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)",
    "inclusion_criteria": "Inclusion Criteria for Cohort 1:\n\n* ECOG performance status (PS) of 0 or 1\n* Histologically confirmed resectable Stage III melanoma according to AJCC-8 and no history of in-transit metastases within the last 6 months\n* Fit and planned for CLND\n* Measurable disease according to RECIST v1.1\n* Availability of a representative tumor specimen\n* Adequate hematologic and end-organ function\n* For patients receiving therapeutic anticoagulation: stable anticoagulant regimen\n* Negative HIV test, negative hepatitis B surface antibody (HBsAb), and negative total hepatitis B core antibody (HBcAb) test, and negative hepatitis C virus (HCV) at screening. Patients with a positive HIV test at screening are eligible provided they are stable on anti-retroviral therapy, have a CD4 count >= 200/μL, and have an undetectable viral load.\n\nExclusion Criteria for Cohort 1:\n\n* Mucosal, uveal and acral lentiginous melanoma\n* Distantly metastasized melanoma\n* History of in-transit metastases within the last 6 months\n* Prior radiotherapy\n* Prior immunotherapy, including anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies, and other systemic therapy for melanoma\n* Treatment with investigational therapy within 28 days prior to initiation of study treatment\n* Treatment with systemic immunostimulatory agents within 4 weeks or 5 drug-elimination half-lives (whichever is longer) prior to initiation of study treatment\n* Prior allogeneic stem cell or solid organ transplantation\n* Known immunodeficiency or conditions requiring treatment with systemic immunosuppressive medication, or anticipation of need for systemic immunosuppressant medication during study treatment\n* Active or history of autoimmune disease or immune deficiency\n\nInclusion Criteria for Cohort 2:\n\n* ECOG PS of 0 or 1\n* Life expectancy >= 3 months, as determined by the investigator\n* Histologically confirmed Stage IV (metastatic) cutaneous melanoma according to AJCC-8\n* Disease progression during or following at least one but no more than two lines of treatment for metastatic disease\n* Measurable disease according to RECIST v1.1\n* Availability of a representative tumor specimen\n* Adequate hematologic and end-organ function\n* For patients receiving therapeutic anticoagulation: stable anticoagulant regimen\n* Negative HIV test, negative hepatitis B surface antibody (HBsAb), and negative total hepatitis B core antibody (HBcAb) test, and negative hepatitis C virus (HCV) at screening. Patients with a positive HIV test at screening are eligible provided they are stable on anti-retroviral therapy, have a CD4 count >= 200/μL, and have an undetectable viral load.\n\nExclusion Criteria for Cohort 2:\n\n* Mucosal and uveal melanoma\n* Treatment with investigational therapy within 28 days prior to initiation of study treatment\n* Treatment with systemic immunostimulatory agents within 4 weeks or 5 drug-elimination half-lives (whichever is longer) prior to initiation of study treatment\n* Prior allogeneic stem cell or solid organ transplantation\n* Known immunodeficiency or conditions requiring treatment with systemic immunosuppressive medication, or anticipation of need for systemic immunosuppressant medication during study treatment\n* Active or history of autoimmune disease or immune deficiency\n* Symptomatic, untreated, or progressing CNS metastases\n* Active or history of carcinomatous meningitis/leptomeningeal disease\n* Uncontrolled tumor-related pain\n* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures\n* Uncontrolled or symptomatic hypercalcemia\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}